Anaplastic Lymphoma Kinase (ALK) Inhibitors: Worldwide Market Analysis & Forecast 2019-2023 with F. Hoffmann-La Roche, Novartis, Pfizer, and Takeda Pharmaceutical Co Dominating - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--May 21, 2019--
The “Global Anaplastic Lymphoma Kinase (ALK) Inhibitors Market 2019-2023” report has been added to ResearchAndMarkets.com’s offering.
The anaplastic lymphoma kinase (ALK) inhibitors market will register a CAGR of about 21% by 2023.
The high prevalence of lung cancer is one of the key factors expected to trigger market growth
The increasing need for treatments coupled with the advances in therapeutics such as targeted therapy is encouraging more and more patients to undergo treatments using ALK inhibitor therapeutics. As a result, owing to the strong incidence rates of the disease and the increasing drug approvals, global ALK inhibitors market will register considerable growth during the forecast period.
Presence of patient assistance programs
Patient assistance programs and reimbursement programs are expected to help with the high-cost regimen of ALK inhibitors to a large extent, which would encourage more patients to avail the treatment, thereby driving the market growth.
Adverse effects associated with therapeutics
Despite being highly efficacious, ALK inhibitors used for treatment NSCLC are associated with a spectrum of side effects. These side effects hinder patient adherence to the treatment, which poses a challenge to market growth.
The market appears to be concentrated. ALK inhibitors have demonstrated efficacy in the oncology indications such as NSCLC, which has been encouraging vendors to extend their application to various other oncology indications through additional clinical trials.
This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
PART 04: MARKET SIZING
PART 05: FIVE FORCES ANALYSIS
PART 06: MARKET SEGMENTATION BY TYPE
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
PART 09: DECISION FRAMEWORK
PART 10: DRIVERS AND CHALLENGES
PART 11: MARKET TRENDS
PART 12: VENDOR LANDSCAPE
PART 13: VENDOR ANALYSIS
For more information about this report visit https://www.researchandmarkets.com/r/qsnck0
View source version on businesswire.com:https://www.businesswire.com/news/home/20190521005807/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 05/21/2019 12:58 PM/DISC: 05/21/2019 12:58 PM